Portfolio Lab

Alnylam Pharmaceuticals, Inc.

  • Stock
  • Ticker ALNY
  • ISIN US02043Q1076
  • Nasdaq

Health care · Pharmaceuticals · USA

$143.82 −2.71%
Close of 20 Nov 2026
Open in backtest

Performance, volatility and drawdowns of Alnylam Pharmaceuticals, Inc. since 11/2016, with distributions reinvested and calculated in US dollars. As of 20 Nov 2026.

Performance

ALNYGlobal equities (VT)

$10,000 grew to $30,503. Global equities (VT): $29,042.

Distributions reinvested, before taxes and brokerage costs. Dashed: Global equities (VT) for comparison.

Declines from the peak

Lowest point −70.7% in 11/2026, measured from the peak in 10/2025. The old peak has not been reached again yet.

1-year return
−67.7%
5-year return p.a.
−4.5%
10-year return p.a.
+11.8%
Volatility p.a.
48.8%
Largest decline
−70.7%

Financial statements

Amounts in $ millions from filings with the SEC, earnings per share in $; fourth quarter and quarterly cash flow derived from year-to-date figures

Quarter end12/202403/202506/202509/202512/202503/202606/202609/2026
Income statement
Revenue5935947741,2491,097–1,2911,458
Gross profit4915246321,052829–9931,096
Operating income-10518-16368132–231346
EBITDA-9132-2.3382145––360
Net income-84-18-722931122061642,167
Earnings per share-0.65-0.14-0.552.140.82–1.2115.72
Balance sheet
Total assets4,2404,2144,5664,8524,966–5,5597,995
Liabilities4,1734,0984,3154,6184,177–4,2054,391
Equity674265555807891,0751,3543,604
Cash9661,0201,1141,4901,657–1,7081,754
Cash flow
Operating cash flow-95-118128297218––341
Capital expenditure-9.1-9.0-14-12-23––-70
Free cash flow-104-127114285194––271

Value it:DCF calculatorMultiples calculator

Annual returns

Best year 2017 at +239.3%, weakest 2018 at −42.6%. 7 of 9 full years were positive. * partial year.

Quarterly reports

Filing date with the SEC and earnings per share of the quarter

DayEarnings per share
29 Oct 2026$15.72
30 Jul 2026$1.21
12 Feb 2026$0.82
30 Oct 2025$2.14
31 Jul 2025−$0.55
1 May 2025−$0.14
13 Feb 2025−$0.65
31 Oct 2024−$0.87
1 Aug 2024−$0.13
2 May 2024−$0.52
15 Feb 2024−$1.09

Key metrics

Metrics of 15 Nov 2026; P/E, P/B, P/S, market cap and dividend yield at the last close.

Valuation

Market cap
€17bn
Market cap in trading currency
$19.3bn
Enterprise value
$15.7bn
P/E
–
P/S
–
P/B
5.35
EV/Sales
–
EV/EBITDA
–
Earnings yield
–
FCF yield
–

Results (last four quarters)

Revenue
–
Gross profit
–
EBITDA
–
Net income
$2.65bn
Earnings per share
–
Revenue per share
–
Revenue growth
+16.7%
Earnings growth
+640.5%

Profitability

Gross margin
–
Operating margin
–
Net margin
–
Return on equity
126.6%
Return on assets
33.1%

Balance sheet and cash flow

Cash
$3.59bn
Cash per share
$26.78
Financial debt
–
Debt/equity %
–
Current ratio
2.48
Book value per share
$26.91
Operating cash flow
–
Free cash flow
–

Dividend

Dividend yield
0.00%
Dividend (12 months)
$0.00
Yield (12 months)
0.00%
Payout ratio
–
Ex-dividend date
–

Shares and trading

Shares outstanding
134m
Volume
2.32m
Avg. volume 3 months
2.06m
Relative volume
1.1

Price and technicals

Price
$143.82
1 day
−2.7%
52-week high
$473.29
52-week low
$143.82
Distance to 52-week high
−69.6%
Distance to 52-week low
0.0%
Distance to 50-day line
−31.1%
Distance to 200-day line
−46.9%
RSI (14)
26
Volatility 1M
107.7%

Performance

1 week
−12.9%
1 month
−36.7%
3 months
−39.1%
6 months
−51.6%
YTD
−63.8%
1 year
−68.8%

Dates

Fiscal year end
31 Dec 2025
Most recent quarter
30 Sep 2026

Frequently asked questions

How has ALNY performed since 11/2016?

$10,000 grew to $30,503 by 20 Nov 2026, which is +11.8% per year. Distributions are reinvested; taxes and brokerage costs are not deducted.

How volatile is ALNY?

Volatility was 48.8% per year, measured on monthly returns. The largest decline from a peak was −70.7%, with the low in 11/2026.

How does ALNY compare with a broad equity ETF?

Over the same period Global equities (VT) returned +11.3% per year at 15.1% volatility, ALNY returned +11.8% at 48.8%. The correlation of monthly returns was 0.21; 1 would mean they moved in lockstep.

Which currency are the figures in?

In US dollars, the currency of the US listing.

Not investment advice. Metrics and financial statements calculated from the company's mandatory filings with the SEC, without guarantee; amounts in US dollars.

Reference data of securities: source ESMA (FIRDS reference data) and SEC (EDGAR).

Not investment advice: results in Portfolio Lab are model calculations based on historical data and your inputs. Past performance is not a reliable indicator of future results.

Alnylam Pharmaceuticals, Inc. (ALNY): Return and risk